Tempus develops AI-enabled precision medicine technology that supports clinical decision-making and biomedical research.
Tempus has raised $400.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in May 2026.
Tempus's investors include Franklin Templeton, Novo Holdings, Ares Management, New Enterprise Associates, Baillie Gifford.
Tempus is headquartered in Chicago, United States.
Tempus develops AI-enabled precision medicine technology that supports clinical decision-making and biomedical research.
Tempus is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tempus — Funding & Investors." VCBacked, May 8, 2026, https://www.vcbacked.co/company/tempus. Accessed July 19, 2026.
VCBacked. (2026). Tempus — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tempus
{{cite web |title=Tempus — Funding & Investors |url=https://www.vcbacked.co/company/tempus |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated